JPWO2019226761A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019226761A5 JPWO2019226761A5 JP2020565359A JP2020565359A JPWO2019226761A5 JP WO2019226761 A5 JPWO2019226761 A5 JP WO2019226761A5 JP 2020565359 A JP2020565359 A JP 2020565359A JP 2020565359 A JP2020565359 A JP 2020565359A JP WO2019226761 A5 JPWO2019226761 A5 JP WO2019226761A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- seq
- pharmaceutical composition
- compound
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 38
- 102100035359 Cerebellar degeneration-related protein 2-like Human genes 0.000 claims description 27
- 101000737792 Homo sapiens Cerebellar degeneration-related protein 2-like Proteins 0.000 claims description 27
- 208000034578 Multiple myelomas Diseases 0.000 claims description 24
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 24
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 14
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 229960004942 lenalidomide Drugs 0.000 claims description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- 208000031223 plasma cell leukemia Diseases 0.000 claims description 3
- 229960000688 pomalidomide Drugs 0.000 claims description 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 2
- 102000046935 human TNFRSF17 Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 description 19
- 239000000126 substance Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023093659A JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675639P | 2018-05-23 | 2018-05-23 | |
| US62/675,639 | 2018-05-23 | ||
| PCT/US2019/033505 WO2019226761A1 (en) | 2018-05-23 | 2019-05-22 | Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093659A Division JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525248A JP2021525248A (ja) | 2021-09-24 |
| JP2021525248A5 JP2021525248A5 (https=) | 2022-05-30 |
| JPWO2019226761A5 true JPWO2019226761A5 (https=) | 2022-05-30 |
| JP7293256B2 JP7293256B2 (ja) | 2023-06-19 |
Family
ID=66999900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565359A Active JP7293256B2 (ja) | 2018-05-23 | 2019-05-22 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
| JP2023093659A Active JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023093659A Active JP7550922B2 (ja) | 2018-05-23 | 2023-06-07 | 併用のためのｂｃｍａ及びｃｄ３に対する抗増殖性化合物及び二重特異性抗体 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11439637B2 (https=) |
| EP (2) | EP4218762A3 (https=) |
| JP (2) | JP7293256B2 (https=) |
| KR (1) | KR102813281B1 (https=) |
| CN (2) | CN112399848B (https=) |
| AU (1) | AU2019274530B2 (https=) |
| BR (1) | BR112020023704A2 (https=) |
| CA (1) | CA3101050A1 (https=) |
| CY (1) | CY1126060T1 (https=) |
| DK (1) | DK3796912T5 (https=) |
| EA (1) | EA202092830A1 (https=) |
| ES (1) | ES2945214T3 (https=) |
| FI (1) | FI3796912T3 (https=) |
| HR (1) | HRP20230449T1 (https=) |
| HU (1) | HUE061792T2 (https=) |
| IL (1) | IL278853B2 (https=) |
| LT (1) | LT3796912T (https=) |
| MX (1) | MX420366B (https=) |
| PL (1) | PL3796912T3 (https=) |
| PT (1) | PT3796912T (https=) |
| RS (1) | RS64189B1 (https=) |
| SG (1) | SG11202011545YA (https=) |
| SI (1) | SI3796912T1 (https=) |
| SM (1) | SMT202300142T1 (https=) |
| WO (1) | WO2019226761A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI791552B (zh) * | 2017-07-10 | 2023-02-11 | 美商西建公司 | 抗增生化合物及其使用方法 |
| BR112020023756A2 (pt) | 2018-05-23 | 2021-02-09 | Celgene Corporation | tratamento de mieloma múltiplo e uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila |
| WO2020097403A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
| JP2020103414A (ja) * | 2018-12-26 | 2020-07-09 | 株式会社三洋物産 | 遊技機 |
| RS67646B1 (sr) * | 2019-01-09 | 2026-02-27 | Celgene Corp | Čvrsti oblici koji obuhvataju (s)-4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-4-il)oksi)metil) benzil)piperazin-1-il)-3-fluorobenzonitril i soli istog, kao i kompozicije koje obuhvataju i metode korišćenja istih |
| WO2020146440A1 (en) * | 2019-01-09 | 2020-07-16 | Celgene Corporation | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
| AU2020206692B2 (en) | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| EP3819007B1 (en) | 2019-11-11 | 2024-07-10 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
| US20230114674A1 (en) * | 2020-01-20 | 2023-04-13 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
| JP2021133198A (ja) * | 2020-02-28 | 2021-09-13 | 株式会社三洋物産 | 遊技機 |
| JP2021133200A (ja) * | 2020-02-28 | 2021-09-13 | 株式会社三洋物産 | 遊技機 |
| JP2021133199A (ja) * | 2020-02-28 | 2021-09-13 | 株式会社三洋物産 | 遊技機 |
| CN116157125A (zh) * | 2020-04-28 | 2023-05-23 | 朱诺治疗学股份有限公司 | 针对bcma的t细胞疗法与免疫调节化合物的组合 |
| JP2023524068A (ja) | 2020-04-30 | 2023-06-08 | ブリストル－マイヤーズ スクイブ カンパニー | サイトカイン関連有害事象を治療する方法 |
| JP2021186294A (ja) * | 2020-05-29 | 2021-12-13 | 株式会社三洋物産 | 遊技機 |
| JP2022012088A (ja) * | 2020-06-30 | 2022-01-17 | 株式会社三洋物産 | 遊技機 |
| JP2022012090A (ja) * | 2020-06-30 | 2022-01-17 | 株式会社三洋物産 | 遊技機 |
| JP2022012089A (ja) * | 2020-06-30 | 2022-01-17 | 株式会社三洋物産 | 遊技機 |
| US12472176B2 (en) | 2020-07-07 | 2025-11-18 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| FI4284512T3 (fi) | 2021-01-28 | 2025-05-22 | Regeneron Pharma | Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi |
| CN119546329A (zh) | 2022-04-11 | 2025-02-28 | 瑞泽恩制药公司 | 用于通用肿瘤细胞杀伤的组合物和方法 |
| KR20250151441A (ko) | 2023-02-17 | 2025-10-21 | 리제너론 파마슈티칼스 인코포레이티드 | Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포 |
| WO2026059921A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| TWI409079B (zh) | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| PL3988117T3 (pl) * | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| US10683369B2 (en) * | 2015-08-03 | 2020-06-16 | Engmab Sàrl | Monoclonal antibodies against BCMA |
| US10238225B2 (en) * | 2016-06-08 | 2019-03-26 | Windor Enterprises, LLC | Compression garment donning aid device, method, and kit |
| WO2018075820A2 (en) | 2016-10-20 | 2018-04-26 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
| EP4295918A3 (en) | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| TWI791552B (zh) * | 2017-07-10 | 2023-02-11 | 美商西建公司 | 抗增生化合物及其使用方法 |
-
2019
- 2019-05-22 EA EA202092830A patent/EA202092830A1/ru unknown
- 2019-05-22 HR HRP20230449TT patent/HRP20230449T1/hr unknown
- 2019-05-22 CN CN201980046500.XA patent/CN112399848B/zh active Active
- 2019-05-22 ES ES19732494T patent/ES2945214T3/es active Active
- 2019-05-22 RS RS20230351A patent/RS64189B1/sr unknown
- 2019-05-22 MX MX2020012485A patent/MX420366B/es unknown
- 2019-05-22 KR KR1020207036733A patent/KR102813281B1/ko active Active
- 2019-05-22 IL IL278853A patent/IL278853B2/en unknown
- 2019-05-22 JP JP2020565359A patent/JP7293256B2/ja active Active
- 2019-05-22 US US16/419,971 patent/US11439637B2/en active Active
- 2019-05-22 SM SM20230142T patent/SMT202300142T1/it unknown
- 2019-05-22 CA CA3101050A patent/CA3101050A1/en active Pending
- 2019-05-22 FI FIEP19732494.0T patent/FI3796912T3/fi active
- 2019-05-22 HU HUE19732494A patent/HUE061792T2/hu unknown
- 2019-05-22 CN CN202110586843.4A patent/CN113713095B/zh active Active
- 2019-05-22 LT LTEPPCT/US2019/033505T patent/LT3796912T/lt unknown
- 2019-05-22 PT PT197324940T patent/PT3796912T/pt unknown
- 2019-05-22 SI SI201930535T patent/SI3796912T1/sl unknown
- 2019-05-22 AU AU2019274530A patent/AU2019274530B2/en active Active
- 2019-05-22 EP EP23156579.7A patent/EP4218762A3/en active Pending
- 2019-05-22 EP EP19732494.0A patent/EP3796912B1/en active Active
- 2019-05-22 PL PL19732494.0T patent/PL3796912T3/pl unknown
- 2019-05-22 BR BR112020023704-3A patent/BR112020023704A2/pt unknown
- 2019-05-22 SG SG11202011545YA patent/SG11202011545YA/en unknown
- 2019-05-22 WO PCT/US2019/033505 patent/WO2019226761A1/en not_active Ceased
- 2019-05-22 DK DK19732494.0T patent/DK3796912T5/da active
-
2022
- 2022-08-17 US US17/820,534 patent/US12053466B2/en active Active
-
2023
- 2023-05-15 CY CY20231100227T patent/CY1126060T1/el unknown
- 2023-06-07 JP JP2023093659A patent/JP7550922B2/ja active Active
-
2024
- 2024-06-25 US US18/753,467 patent/US20240366593A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525248A5 (https=) | ||
| JPWO2019226761A5 (https=) | ||
| HRP20230449T1 (hr) | Antiproliferativni spojevi i bispecifična protutijela protiv bcma i cd3 za kombiniranu upotrebu | |
| KR102171669B1 (ko) | 조합물 및 이의 용도 | |
| EP3678700B1 (en) | Compounds for reducing the viscosity of biological formulations | |
| JP2018506550A5 (https=) | ||
| JP7160533B2 (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| JP6184952B2 (ja) | 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 | |
| JP2021514003A5 (https=) | ||
| JP2020532562A5 (https=) | ||
| TWI910300B (zh) | 預防或治療ｅｇｆｒ功能異常相關的副作用的方法 | |
| CN105899536A (zh) | 用抗cxcr4抗体治疗c1013g/cxcr4相关的华氏巨球蛋白血症 | |
| JP2014525926A5 (https=) | ||
| JP7761490B2 (ja) | 小細胞肺がんの併用療法用キノリン誘導体 | |
| JP2018533569A5 (https=) | ||
| MD3630177T2 (ro) | Paradigmă de tratament pentru un tratament combinat cu anticorpi anti-CD19 și venetoclax | |
| CN118922208A (zh) | 用于消耗患病造血干细胞的组合物和方法 | |
| JP2023011549A5 (https=) | ||
| CN118697865A (zh) | 治疗淋巴瘤的药物组合 | |
| JPWO2022117799A5 (https=) | ||
| JP2025537529A (ja) | リヒター症候群を治療するためのｃｄ３およびｃｄ２０に対する二重特異性抗体 | |
| JP2020507569A5 (https=) | ||
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| JPWO2021178657A5 (https=) | ||
| CN115515978A (zh) | 用于治疗呼吸系统疾病的pan-elr+cxc趋化因子抗体 |